The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Tandem Meetings 2026 | Real-world outcomes of bispecific antibody treatment in patients with double-hit lymphoma
In this video, Geoffrey Shouse, DO, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, presents the findings from a real-world evidence study evaluating outcomes of bispecific antibody treatment in patients with double-hit lymphoma, a high-risk subgroup of large B-cell lymphoma (LBCL). Double-hit disease was defined as patients with MYC and BCL2 translocations, with some patients also harboring BCL6 translocations. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this was a large multi-center study from the CUBIC consortium. So it includes 10 centers across the U.S. with a focus on outcomes for bispecific antibodies. This is a large retrospective study where we were specifically evaluating outcomes of patients with double-hit lymphoma or high-grade B-cell lymphoma with MYC and BCL2 translocations. So we defined double-hit lymphoma as patients with either MYC and BCL2 or MYC, BCL2, and BCL6...
So this was a large multi-center study from the CUBIC consortium. So it includes 10 centers across the U.S. with a focus on outcomes for bispecific antibodies. This is a large retrospective study where we were specifically evaluating outcomes of patients with double-hit lymphoma or high-grade B-cell lymphoma with MYC and BCL2 translocations. So we defined double-hit lymphoma as patients with either MYC and BCL2 or MYC, BCL2, and BCL6. So we did not include patients with just MYC and BCL6 translocations.
And all in all, we had 58 patients that were included in the study. The majority received glofitamab and epcoritamab, with three patients receiving mosunetuzumab and polatuzumab. As far as the response rates, overall response rate is 48%, so maybe numerically a little bit lower than what we’ve seen overall for large cell lymphoma, and a CR rate of about 29%, so probably a little bit lower than what we see in non-double hit. Cytokine release syndrome occurred in 38%, maximum was grade three. And neurologic toxicity occurred in 12%, max grade four in just two patients.
I think the survival outcomes were probably the most important for the study. So progression-free survival at 10 months of follow-up the median was 2.99 months, with the one-year PFS of only 26%. So overall, patients didn’t have the best survival outcomes if they had double-hit disease, although compared to other treatments in this space, bispecific antibodies are probably still better than other alternatives. Interestingly, if we look at patients who achieved CR, which was about 29% of patients, the one-year PFS was 68%. So if patients could achieve a complete response, their survival is certainly better. One-year overall survival is 48% with a median of almost 10 months. So overall, bispecific antibodies do well with double-hit lymphoma, but in this setting, where patients are heavily pre-treated, including prior CAR-T and a significant percentage, the outcomes are suboptimal.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Abbvie, ADC Therapeutics, Astra Zeneca, BMS, BeOne Medicines, Kite Pharma, Merck; Prior Speakers Bureaus: ADC Therapeutics, BeOne Medicines, Kite Pharma.
